To take advantage of the synergistic action, we incorporated IL2 and IL12 into a dual cytokine fusion protein linked to the anti-CD30-scFv antibody for targeting the cytokines toward Hodgkin's lymphoma cells. Here, TNFRSF8 is linked to Hodgkins lymphoma.